Feedback
Cerdelga® (eliglustat) Panel, Peak Levels
2010979
Ordering Recommendation
Mnemonic
ELIG PK
Methodology
UPLC-Tandem Mass Spectrometry
Performed
Varies, performed twice per week
Reported
3-7 days
N/A
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
The first specimen should be collected just prior to administration of a scheduled dose of eliglustat (Cerdelga).  After the first draw (0 minutes), the patient should immediately be administered an eliglustat dose and the time recorded. Times of previous and current dose must be submitted with the order.  
Collect
Four timed specimens in Lavender (EDTA) tubes.  Collect at 0 minutes (before eliglustat administration) and repeat collections 1 hour, 2 hours, and 3 hours after eliglustat administration (three separate one hour intervals between collections).  Accurately record the time of each collection.  
Specimen Preparation
For each time point collected, separate plasma from cells ASAP.  Transfer 1mL(min 0.2mL) plasma per time point to an individual ARUP standard transport tube, label with the time point (0 min, 1hr, 2hr, or 3 hr) and freeze immediately.   Transport tubes and labeling kit (ARUP supply #51730) available online through eSupply using ARUP Connect™ or contact Client Services at (800)522-2787. 
Storage/Transport Temperature
Critical Frozen 
Unacceptable Conditions
Plasma collected in Gray (sodium fluoride/potassium oxalate), Green (sodium/lithium heparin), or Light Blue (sodium citrate) tubes.  Serum (Red, Gold, or Separator tubes).  
Remarks
For more information on this test, see www.aruplab.com/cerdelga
For requisition information, see www.aruplab.com/cerdelga/requisitions 
Stability
Ambient: unacceptable; Refrigerated: unacceptable; Frozen: 2 weeks; avoid repeated freeze/thaw cycles. 
Reference Interval
Interpretive Data
Results should be considered in conjunction with the patient's clinical history and clinical presentation. For additional information, inquire Genzyme Medical Information at medinfo@genzyme.com, or 800-745-4447 (option 2).

Note
Lipemia: At eliglustat concentration of <5 ng/mL, artificially low values (-28 percent lower than actual) were observed in the presence of triglyceride-rich lipoproteins (500 mg/dL).
Components
Component Test Code*Component Chart NameLOINC
2010981Eliglustat, 0 min
2010983Eliglustat, 1 hr post dose
2010985Eliglustat, 2 hr post dose
2010987Eliglustat, 3 hr post dose
2010988Time of dose at 0 min
2010989Time of previous dose
2010992Time of collection 0 min
2010993Time of collection 1 hr
2010994Time of collection 2 hr
2010995Time of collection 3 hr
2011662Eliglustat Peak Panel Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Cerdelga
  • Eliglustat Peak Level
  • Gaucher